Details for Patent: 9,266,861

Which drugs does patent 9,266,861 protect, and when does it expire?

Patent 9,266,861 protects REZDIFFRA and is included in one NDA.

This patent has sixty-six patent family members in twenty-one countries.

Summary for Patent: 9,266,861

Title:	Method of synthesizing thyroid hormone analogs and polymorphs thereof
Abstract:	The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.
Inventor(s):	Hester, II D. Keith, Duguid Robert J., Kelly Martha J., Chasnoff Anna, Dong Gang, Crow Edwin L., Choi Duk Soon, Shu Lianhe, Wang Ping
Assignee:
Application Number:	US14660720
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 9,266,861

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-001	Mar 14, 2024		RX	Yes	No			Y	Y
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No			Y	Y
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-003	Mar 14, 2024		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,266,861

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	092872
Australia	2013315017
Brazil	112015005891
Brazil	122021024202
Canada	2884481
Canada	3090070